Literature DB >> 22153859

Coronary artery perfusion and myocardial performance after patent ductus arteriosus ligation.

Arvind Sehgal1, Patrick J McNamara.   

Abstract

OBJECTIVES: To study coronary artery (CA) perfusion and myocardial performance after patent ductus arteriosus (PDA) ligation. The postoperative course in premature infants undergoing surgical ligation of PDA is often complicated by cardiorespiratory instability secondary to impaired left ventricular performance.
METHODS: Serial echocardiography was performed before and after (1, 8, and 24 hours) PDA ligation to assess systolic (left ventricular output [LVO]) and diastolic (isovolumic relaxation time, E and A wave peak velocity) myocardial performance, and CA diastolic flow (CA velocity time integral and flow). The ratio of CA flow to LVO was calculated as a surrogate of coronary flow.
RESULTS: A total of 20 infants (gestational age at birth, 26.3 ± 0.7 weeks) requiring PDA ligation at a median of 28.5 days (range, 9-40) after birth and weight of 780 g (range, 570-2840) were studied. A postoperative increase in the CA flow/LVO ratio was demonstrated. An early decrease in E and A wave peak velocity (P < .05) and increase in isovolumic relaxation time (P < .05) were demonstrated at 1 hour, before any clinical deterioration. A low baseline CA velocity time integral was associated with a low E/A ratio (r = 0.63, P = .01) at 1 hour and lower systolic blood pressure at 8 hours (r = 0.5, P = .05). The postoperative need for inotropes (n = 8) was associated with a low baseline CA velocity time integral at 1 hour (r = 0.52, P < .05), low LVO at 1 and 8 hours (P < .05), and increased oxygen requirement at 24 hours (P < .05).
CONCLUSIONS: PDA ligation is followed by altered CA perfusion. Perioperative evaluation of the CA perfusion can help identify neonates at risk of impaired myocardial performance, systolic hypotension, and the need for inotropes.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22153859     DOI: 10.1016/j.jtcvs.2011.10.035

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Reduced cardiac output and its correlation with coronary blood flow and troponin in asphyxiated infants treated with therapeutic hypothermia.

Authors:  Arvind Sehgal; Flora Wong; Shailender Mehta
Journal:  Eur J Pediatr       Date:  2012-06-06       Impact factor: 3.183

2.  Interparametric correlation between echocardiographic markers in preterm infants with patent ductus arteriosus.

Authors:  Arvind Sehgal; Samuel Menahem
Journal:  Pediatr Cardiol       Date:  2013-01-31       Impact factor: 1.655

3.  Potential Unintended Consequences of a Conservative Management Strategy for Patent Ductus Arteriosus.

Authors:  Justin J Elhoff; Myla Ebeling; Thomas C Hulsey; Andrew M Atz
Journal:  Congenit Heart Dis       Date:  2015-07-20       Impact factor: 2.007

Review 4.  Myocardial Infarction in Neonates: A Review of an Entity with Significant Morbidity and Mortality.

Authors:  Koyelle Papneja; Anthony K Chan; Tapas K Mondal; Bosco Paes
Journal:  Pediatr Cardiol       Date:  2017-02-25       Impact factor: 1.655

5.  Cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus: effects on cardiac and vascular indices.

Authors:  Arvind Sehgal; Tejas Doctor; Samuel Menahem
Journal:  Pediatr Cardiol       Date:  2014-06-04       Impact factor: 1.655

Review 6.  Patent ductus arteriosus ligation and adverse outcomes: causality or bias?

Authors:  Dany E Weisz; Patrick J McNamara
Journal:  J Clin Neonatol       Date:  2014-04

Review 7.  Patent Ductus Arteriosus Clinical Trials: Lessons Learned and Future Directions.

Authors:  Aisling Smith; Afif El-Khuffash
Journal:  Children (Basel)       Date:  2021-01-15

Review 8.  Hemodynamic consequences of respiratory interventions in preterm infants.

Authors:  Arvind Sehgal; J Lauren Ruoss; Amy H Stanford; Satyan Lakshminrusimha; Patrick J McNamara
Journal:  J Perinatol       Date:  2022-06-11       Impact factor: 3.225

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.